Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Study of Ultratrace Iobenguane I 131 [iodine I 131 metaiodobenzylguanidine] in Patients With Relapsed/Refractory High-Risk Neuroblastoma.

Next Previous
Trial Profile

A Phase 2a Study of Ultratrace Iobenguane I 131 [iodine I 131 metaiodobenzylguanidine] in Patients With Relapsed/Refractory High-Risk Neuroblastoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Sponsors Molecular Insight Pharmaceuticals

Most Recent Events

  • 18 Mar 2019 Results of a pooled analysis from NCT00339131; NCT00458952; NCT00874614; NCT00659984 trials presented at the 101st Annual Meeting of the Endocrine Society
  • 02 Aug 2012 Actual end date Nov 2010 added as reported by ClinicalTrials.gov.
  • 07 Oct 2010 Planned end date changed from 1 Oct 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top